Emgality Dosing for Migraine Prophylaxis
For migraine prevention in adults, initiate Emgality (galcanezumab) with a 240 mg loading dose (two consecutive 120 mg subcutaneous injections) followed by 120 mg monthly thereafter. 1
Dosing Regimen
The FDA-approved dosing is straightforward and non-negotiable:
- Loading dose: 240 mg subcutaneously (administered as two consecutive 120 mg injections) at initiation
- Maintenance dose: 120 mg subcutaneously once monthly
- Route: Subcutaneous injection only
- Injection sites: Abdomen, thigh, back of upper arm, or buttocks (avoid tender, bruised, red, or hard areas)
Administration Essentials
Critical preparation steps:
- Allow Emgality to reach room temperature for 30 minutes before injection
- Do NOT warm using heat sources (hot water, microwave)
- Do NOT shake the product
- Inspect visually—discard if cloudy or contains visible particles
- Protect from direct sunlight
Evidence Supporting This Regimen
The 240 mg loading dose followed by 120 mg monthly is supported by robust phase 3 trial data. In the EVOLVE-1 and EVOLVE-2 studies of episodic migraine patients, this regimen reduced monthly migraine headache days by approximately 4.3-4.7 days compared to 2.3-2.8 days with placebo over 6 months 1. Importantly, the 240 mg monthly maintenance dose showed no additional benefit over 120 mg monthly, which is why the lower maintenance dose is recommended 1.
The 2025 American College of Physicians guideline includes galcanezumab among CGRP monoclonal antibodies as a conditional recommendation for episodic migraine prevention, though it does not specify dosing details 2.
Clinical Response Timeline
- Onset: Reductions in migraine days begin within the first month
- Sustained effect: Benefits persist throughout 12 months of treatment 3, 4
- Response rates at 6 months: Approximately 59-62% of patients achieve ≥50% reduction in monthly migraine headache days 1
- Persistence: About 41% of episodic migraine patients maintain ≥50% response for ≥3 consecutive months 4
Missed Dose Management
If a dose is missed, administer as soon as possible. Then resume monthly dosing from the date of that last dose 1.
Safety Considerations
Monitor for hypersensitivity reactions (including anaphylaxis, angioedema, dyspnea, urticaria, rash), which can occur days after administration and may be prolonged. Discontinue immediately if serious hypersensitivity occurs 1.
Monitor blood pressure, as CGRP antagonists including galcanezumab can cause new-onset hypertension or worsen pre-existing hypertension, particularly in patients with risk factors 1.
Common adverse events include injection site reactions and constipation, with overall adverse event rates of approximately 25% at 6 months 5.
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab or any excipients 1.
Special Populations
No dose adjustments are needed based on age, sex, weight, race, or ethnicity. Renal or hepatic impairment are not expected to affect pharmacokinetics, though severe renal impairment (CrCl <30 mL/min) has not been studied 1.